By studying the effects of 3-deazaneplanocin A (DZNep), a histone methyltransferase EZH2 inhibitor, on human T-cell acute lymphoid leukaemia (T-ALL) cells, Shen et al. found that DZNep treatment reduced histone methylation in hMOB1 promoters, resulting in an upregulation of hMOB1 expression associated with inhibited growth of T-ALL cells [156]. This evidence concerns the gene EZH2 and acute lymphoblastic leukemia.